Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
Recruiting now · Phase 1
Conditions studied: Hepatocellular Carcinoma
In brief
The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma. The main questions it aims to answer are: * Objective response rate (ORR) for evaluation * Disease Control Rate (DCR); Duration of relief (DoR); Progression free survival (PFS); Total survival time (OS); Safety。
Key facts
- Study ID
- NCT06363006
- Run by
- Peking Union Medical College Hospital
- People needed
- 40
- Starts
- 2024-03-11
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2024-04-12
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH) — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.